FREMONT, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Protein Design Labs,
Inc. (PDL) (Nasdaq: PDLI) today announced that it will conduct a live webcast
of its R&D Update presentation to the financial community. The live webcast
will begin at 8:00 a.m. Eastern time on October 15, and is expected to
conclude by 10:30 a.m. Eastern time.
Mark McDade, Chief Executive Officer, will host the PDL R&D Update and
webcast. Joining him from the company will be Steven Benner, M.D., Senior
Vice President and Chief Medical Officer, Richard Murray, Ph.D., Senior Vice
President and Chief Scientific Officer, and Glen Y. Sato, Senior Vice
President and Chief Financial Officer.
In addition, Scott Plevy, M.D., Associate Professor of Medicine, Division
of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, will
discuss recently reported interim data from the Phase I dose-ranging portion
of a Phase I / II clinical trial of Nuvion(R) (visilizumab) in severe
ulcerative colitis; Eric Rowinsky, M.D., Clinical Professor of Medicine,
University of Texas Health Science Center and Senior Scientist, CTRC Institute
for Drug Development, San Antonio, Texas, will present a discussion of interim
Phase I clinical trial results for M200 (anti-alpha5beta1 integrin antibody)
in solid organ tumors; and Elliot Israel, M.D., Director of Respiratory
Therapy and Pulmonary Clinical Research, Brigham & Women's Hospital and
Associate Professor of Medicine, Harvard Medical School, will deliver a
presentation on Phase II data for Zenapax(R) (daclizumab) in moderate-to-
severe persistent asthma.
PDL will also update the clinical development plans and timelines for its
products in development, including Nuvion(R), daclizumab, HuZAF(TM)
(fontolizumab) and M200, and discuss status of several programs in
preclinical-stage development, including the F200 antibody fragment.
The live webcast will be available through the PDL website: http://www.pdl.com.
Please connect to this website at least 15 minutes prior to the live webcast
to allow time for any software download that may be needed to hear the
webcast. A replay, including the presentation materials, will be available at
http://www.pdl.com starting approximately one hour after completion of the webcast.
Protein Design Labs is a leader in the development of humanized antibodies
to prevent or treat various disease conditions. PDL currently has antibodies
under development for autoimmune and inflammatory conditions, asthma and
cancer. PDL holds fundamental patents for its antibody humanization
technology. Further information on PDL is available at http://www.pdl.com.
NOTE: Protein Design Labs, the PDL logo and Nuvion are registered U.S.
trademarks of Protein Design Labs, Inc. Zenapax is a registered trademark of
Roche.
SOURCE Protein Design Labs, Inc.
 back to top
Related links:
http://www.pdl.com
CONTACT:
James R. Goff, Senior Director, Corporate
Communications of Protein Design Labs, Inc., +1-510-574-1421, or
jgoff@pdl.com
|
